U.K. cost gatekeepers OK Daiichi's Lixiana; J&J Vision Care targets young females with E! partnership;

> The U.K.'s cost watchdog has recommended Daiichi Sankyo's Lixiana for treating and preventing potentially fatal blood clots. Release

> In a Phase II study, Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 prospect, Praluent, produced LDL cholesterol reductions of more than 60% in Japanese patients. Release

> Johnson & Johnson ($JNJ) Vision Care has partnered up with fashion and entertainment broadcaster E! Entertainment Television to reach a young, fashion-forward, female audience with its 1-Day Acuvue Define range of products. More

> In a Phase II study, Roche's ($RHHBY) investigational immunotherapy atezolizumab shrank tumors in people with a specific type of bladder cancer. Release

> Roche ($RHHBY) has launched its FDA-cleared diabetes app with an insulin calculator in the U.S. More

And Finally... The Obama administration has issued new rules that allow closely held for-profit corporations with religious objections to opt out of providing women with insurance coverage for contraceptives. More (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.